12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke | Zendy

Yü Liu | Zendy; Yi Zheng | Zendy; Hülya Karataş | Zendy; Xiaoying Wang | Zendy; Christian Foerch | Zendy; Eng H. Lo | Zendy; Klaus van Leyen | Zendy

Open Access

12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke

Author(s) -

Yü Liu,

Yi Zheng,

Hülya Karataş,

Xiaoying Wang,

Christian Foerch,

Eng H. Lo,

Klaus van Leyen

Publication year - 2017

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.014790

Subject(s) - medicine , warfarin , stroke (engine) , ischemia , atrial fibrillation , plasminogen activator , tissue plasminogen activator , prothrombin time , knockout mouse , brain ischemia , anticoagulant , pharmacology , anesthesia , receptor , mechanical engineering , engineering

For stroke prevention, patients with atrial fibrillation typically receive oral anticoagulation. The commonly used anticoagulant warfarin increases the risk of hemorrhagic transformation (HT) when a stroke occurs; tissue-type plasminogen activator treatment is therefore restricted in these patients. This study was designed to test the hypothesis that 12/15-lipoxygenase (12/15-LOX) inhibition would reduce HT in warfarin-treated mice subjected to experimental stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research